Neurogenerative Diseases - 15

References

Figure 4. Assessment of Tau antibody specificity (A) Western blot analysis of Tau antibody (clone TAU-5, Cat. No. MA5-12808) across multiple
cell lines. (B) Immunofluorescence analysis in human iPSC-derived forebrain organoids at day 40 using Tau antibody (green; clone TAU-5, Cat.
No. AHB0042) and phospho-Tau [pS396] (red, Cat. No. 44-752G); data
courtesy of Zhexing Wen, Emory University. (C) Western blot analysis of
phospho-Tau [pS199, pS202] antibody (Cat. No. 44-768G), showing loss
of signal with specific peptide and not with other nonrelevant peptides.
(D) Western blot analysis of phosphor-Tau [pSer262] antibody (Cat. No.
44-750G) in mouse brain, rat brain, and mouse kidney lysates. For the
western blot analysis, primary antibodies were probed with Invitrogen™
Goat Anti-Rabbit IgG or Goat Anti-Mouse IgG Secondary Antibody, HRP
(Cat. No. G21234, Cat. No. 62-6520), detected using the Thermo Scientific™ Pierce™ ECL Western Blotting Substrate (Cat. No. 32106), and imaged
using the Invitrogen™ iBright™ FL1000 imaging system.

Find antibodies for PD research
Although the implication of genes and proteins in PD
continues to grow, a majority of them have been a
challenge to study, given their relative low abundance
in vitro and a lack of quality reagents to understand
their function. Invitrogen™ antibodies are tested in
relevant models and applications and confirmed
for specificity using siRNA/CRISPR-mediated gene
silencing, relative expression, and cell treatment.
Learn more about our expanded antibody validation
methods at thermofisher.com/antibodyvalidation
and search our complete portfolio of primary
antibodies at thermofisher.com/antibodies.

Additional Resources
Invitrogen Antibody Validation

15

1.

Gundersen V (2010) Acta Neurol Scand 2010 122 (Suppl 190):82-87.

2.

Irvine GB, El-Agnaf OM, Shankar GM et al. (2008) Mol Med 14:451-464.

3.

Braak H, Del Trecdici K (2016) Cold Spring Harb Perspect Biol
8:a023630.

4.

Zhang X, Gao F, Wang D et al. (2018) Front Neurol 9:809.

5.

Moussaud S, Jones DR, Moussaud-Lamodière et al. (2014) Mol
Neurodegener 9:43.

6.

Ebrahimi-Fakhari D, Wahlster L, McLean PJ (2012) Acta Neuropathol
124:153-172.

7.

Bharadwaj S, Ali A, Ovsenek N (1999) Mol Cell Biol 19:8033-8041.

8.

Aguzzi A, Lakkaraju AKK (2016) Trends Cell Biol 26:40-51.

9.

9. Vasili E, Dominguez-Meijide A, Outeiro TF (2019) Front Mol
Neurosci 12:107.

10.

Polymeropoulos MH, Lavedan C, Leroy E et al. (1997) Science
276:2045-2047.

11.

Spillantini MG, Crowther RA, Jakes R et al. (1998) Proc Natl Acad Sci U
S A 95:6469-6473.

12.

Hsu LJ, Sagara Y, Arroyo A et al. (2000) Am J Pathol 157:401-410.

13.

Bourdenx M, Dehay B, Bezard E (2014) Front Neuroanat 8:83.

14.

Guttuso T Jr, Andrzejewski KL, Lichter DG et al. (2019) J Neurol Sci
402:121-130.

15.

Zhi L, Qin Q, Muqeem T et al. (2019) Neurobiol Aging 75:1-10.

16.

Karunanithi S, Brown IR (2015) Front Cell Neurosci 9:68.

17.

Gauthier-Kemper A, Weissmann C, Golovyashkina N et al. (2011) J Cell
Biol 192:647-661.

18.

Tardivel M, Bégard S, Bousset L et al. (2016) Acta Neuropathol
Commun 4:117.

19.

Chen J, Kanai Y, Cowan NJ et al. (1992) Nature 360:674-677.

20.

Brandt R, Léger J, Lee G (1995) J Cell Biol 131:1327-1340.

21.

Lei P, Ayton S, Finkelstein DI et al. (2010) Int J Biochem Cell Biol
42:1775-1778.
http://www.thermofisher.com/antibodyvalidation http://www.thermofisher.com/antibodies http://thermofisher.com/antibodyvalidation
Neurogenerative Diseases

Table of Contents for the Digital Edition of Neurogenerative Diseases
